Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Description

Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS

Conditions

Myelodysplastic Syndromes, Adult

Study Overview

Study Details

Study overview

Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS

Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Condition
Myelodysplastic Syndromes, Adult
Intervention / Treatment

-

Contacts and Locations

Burlington

University of Vermont, Burlington, Vermont, United States, 05495-2038

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years
  • * Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
  • * Eastern Cooperative Oncology Group (ECOG) performance status ≤3
  • * Expected survival of at least 6 months
  • * Ability to provide consent
  • * Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
  • * Hematopoietic stem cell transplantation expected within 6 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Vermont,

Study Record Dates

2027-11